What Is Press'd 7-OH? Product Guide and What the DEA Ban Means

Press'd is one of the more widely distributed brands in the 7-hydroxymitragynine tablet category. If you have encountered the name at a smoke shop or on a reseller site and want a straight explanation of what the products are and how the Drug Enforcement Administration's July 2026 action applies to them, this guide covers both.

We sell Cat's Claw botanicals, not kratom products, so it is fair to note our position up front. That is also why the rest of this article sticks to published specifications and to the text of the federal notices. Press'd is a legitimately operating brand and nothing below is an accusation against it. Product lines in this category change frequently, so treat any specification as a snapshot and check the package in front of you.

What Press'd Products Are

Press'd makes pressed tablets and liquid shots whose labeled active ingredient is 7-hydroxymitragynine, commonly shortened to 7-OH. 7-OH is a minor alkaloid found naturally in kratom leaf (Mitragyna speciosa) at very small concentrations. The material used in concentrated tablet products is not raw leaf — it is an extract or a semi-synthetic conversion product, which is how a tablet can carry tens or hundreds of milligrams of a compound that appears in the leaf only in trace amounts.

The brand has been in the 7-OH space since relatively early in the category's development and is often cited as one of the first to build tablet products around specific leaf strain profiles. Its catalog has since broadened well past a single SKU.

Published Product Specifications

Across the brand's own listings and its authorized resellers, the Press'd catalog spans a wide potency range. The table below reflects specifications published by retailers at the time of writing.

Two cautions on reading that table. First, some retailer listings advertise a pack total rather than a per-tablet figure — a listing headlined "10ct 180mg," for example, is describing the package, not the tablet. Second, the URIQ Complex line is labeled as a botanical complex and its alkaloid composition is not broken out in the listings we reviewed, so we are not characterizing what is in it.

Why the MGM-15 Line Matters Here

One item in the catalog above is worth flagging separately. Alongside 7-OH, the DEA's July 2026 action also covers MGM-15, MGM-16, and mitragynine pseudoindoxyl. Press'd publishes a tablet line named for MGM-15, and a line named for pseudoindoxyl content. Those named compounds fall under the second of the two notices the DEA filed — the one that does not carry the same above-a-threshold qualifier that applies to 7-OH.

We are reporting the product names as published. We have not tested these products and make no claim about what any given batch actually contains.

What the DEA Action Says

On July 1, 2026, the DEA filed Notices of Intent to temporarily place 7-hydroxymitragynine above a specified threshold into Schedule I of the Controlled Substances Act, along with mitragynine pseudoindoxyl, MGM-15, and MGM-16. The notices published in the Federal Register on July 6, 2026. You can read the agency's announcement at dea.gov.

The key dates and figures:

• Earliest order date: the temporary scheduling order will not issue before August 5, 2026.
• Duration: two years, during which the agency can pursue permanent scheduling.
• Threshold for leaf material: 0.05% 7-OH.
• Threshold for extracts, concentrates, edibles, and pressed pills: 0.05% or 1mg per article.

That last line is the operative one for this category. The threshold is deliberately set at a level that natural leaf does not reach on its own. A pressed tablet containing 18mg, 40mg, 110mg, or 250mg of 7-OH per unit is far above 1mg per article — by one to two orders of magnitude or more. Every 7-OH tablet strength published by Press'd, and by every other brand in this category, sits above the line by a wide margin.

We walk through the arithmetic and the "per article" definition in more detail in the 7-OH threshold explained, and address the broader question people are actually asking in is 7-OH banned.

What Changes on or After August 5

Once a temporary scheduling order issues, Schedule I controls attach to the covered substances. In practical terms that reaches manufacturing, distribution, importing, exporting, and research involving material above the threshold. Schedule I is the most restrictive category in the Controlled Substances Act and it carries registration requirements that ordinary retail supply chains are not built to satisfy.

What this means concretely for anyone who currently buys Press'd or any comparable brand:

• The change is federal and applies nationwide. It is not a state-by-state patchwork like some previous kratom rules.
• It is driven by concentration and quantity, not by brand. No brand in the concentrated 7-OH tablet category is positioned differently from any other under this threshold.
• It is temporary in the technical sense — two years — but two years is long enough that treating it as a short pause would be a misreading.
• The specific effective date depends on when the order actually publishes. August 5, 2026 is the earliest possible date, not a guaranteed one.

None of this is a statement that Press'd has done anything wrong. The brand has operated in a category that was legal to sell and is now being scheduled. That is a regulatory shift, not a finding against any company.

Looking at kratom-free options?

Some consumers are using the run-up to August 5 as a prompt to look at what else is on the shelf. Botanical products exist that contain no kratom and no 7-OH at all — different plants entirely, with their own alkaloid profiles and their own regulatory status. Cat's Claw (Uncaria tomentosa) is one of them, and it is what we work with.

These are not substitutes and we are not going to describe them as producing any particular result. They are separate botanicals, and worth evaluating on their own terms. If you want to read up first, we have a plain-language primer at what is Cat's Claw, batch documentation at our COA page, and the products themselves in the Cat's Claw collection.

Frequently Asked Questions

What is 7-OH?

7-hydroxymitragynine is a minor alkaloid that occurs naturally in kratom leaf at trace concentrations. Concentrated tablet and shot products use extracted or converted material rather than raw leaf, which is how they reach the milligram loads printed on their labels.

How strong are Press'd tablets?

It depends entirely on the line. Published per-tablet figures range from 18mg up to 250mg for the MAX line, with a 40mg liquid shot also listed. Some retailer headlines quote a pack total rather than a per-tablet number, so read the fine print.

What happens to 7-OH products like these after August 5, 2026?

The DEA's temporary scheduling order will not issue before August 5, 2026, and it applies to 7-OH above 0.05% or 1mg per article — a threshold that concentrated 7-OH tablets exceed across the category. Once an order issues, Schedule I controls attach to covered material. We are describing the scheduling action and its stated threshold; we are not offering legal advice, and anyone who needs a determination about their own situation should consult a qualified attorney.

Does the ban apply to plain kratom leaf?

The 7-OH notice is written around a threshold of 0.05% for leaf material. Natural leaf ordinarily contains 7-OH well below that level. The action was aimed at concentrated and enhanced products rather than at leaf as such, though the related-substances notice covering pseudoindoxyl, MGM-15, and MGM-16 is written differently.

How long does the temporary scheduling last?

Two years from the date the order issues, during which the DEA may move toward permanent scheduling.

These statements have not been evaluated by the U.S. Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. For adults 21+. Consult a qualified healthcare professional before use.